Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) SVP Jolanda Howe Sells 375 Shares

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) SVP Jolanda Howe sold 375 shares of the company’s stock in a transaction on Tuesday, July 2nd. The shares were sold at an average price of $34.00, for a total transaction of $12,750.00. Following the completion of the transaction, the senior vice president now owns 2,426 shares of the company’s stock, valued at $82,484. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Mirum Pharmaceuticals Price Performance

NASDAQ MIRM traded up $0.20 on Wednesday, hitting $33.88. 222,124 shares of the company were exchanged, compared to its average volume of 623,462. The firm has a 50 day moving average of $27.01 and a two-hundred day moving average of $27.21. The company has a market cap of $1.60 billion, a P/E ratio of -9.08 and a beta of 1.15. The company has a current ratio of 3.68, a quick ratio of 3.47 and a debt-to-equity ratio of 1.31. Mirum Pharmaceuticals, Inc. has a 1-year low of $23.14 and a 1-year high of $35.56.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its earnings results on Wednesday, May 8th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.14). Mirum Pharmaceuticals had a negative net margin of 69.67% and a negative return on equity of 56.46%. The business had revenue of $69.22 million for the quarter, compared to analyst estimates of $69.71 million. On average, equities analysts predict that Mirum Pharmaceuticals, Inc. will post -1.66 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research firms have commented on MIRM. Robert W. Baird increased their price objective on shares of Mirum Pharmaceuticals from $34.00 to $39.00 and gave the company an “outperform” rating in a research note on Monday, June 17th. Cantor Fitzgerald reissued an “overweight” rating and set a $40.00 target price on shares of Mirum Pharmaceuticals in a research note on Thursday, May 9th. JPMorgan Chase & Co. raised their price objective on shares of Mirum Pharmaceuticals from $31.00 to $39.00 and gave the company an “overweight” rating in a research report on Tuesday, June 18th. SVB Leerink reduced their price objective on shares of Mirum Pharmaceuticals from $44.00 to $43.00 and set an “outperform” rating for the company in a research report on Monday, March 18th. Finally, JMP Securities raised their target price on shares of Mirum Pharmaceuticals from $66.00 to $68.00 and gave the stock a “market outperform” rating in a report on Tuesday, June 18th. Ten analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $53.64.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in MIRM. AJOVista LLC bought a new stake in Mirum Pharmaceuticals during the 4th quarter worth approximately $40,000. Wetzel Investment Advisors Inc. bought a new stake in Mirum Pharmaceuticals during the 4th quarter worth approximately $41,000. StepStone Group LP bought a new stake in Mirum Pharmaceuticals during the 4th quarter worth approximately $135,000. China Universal Asset Management Co. Ltd. grew its stake in shares of Mirum Pharmaceuticals by 447.1% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 5,394 shares of the company’s stock worth $159,000 after acquiring an additional 4,408 shares in the last quarter. Finally, Quest Partners LLC bought a new position in shares of Mirum Pharmaceuticals during the 4th quarter worth approximately $194,000.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.